This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
ETF Investing Areas to Consider for August
by Sweta Jaiswal, FRM
Let's take a look at some ETF areas that can be good investment options for August.
IBBNegative Net Change XLKNegative Net Change SDYPositive Net Change VIGNegative Net Change NOBLPositive Net Change XBINegative Net Change DVYPositive Net Change BBHPositive Net Change IYWNegative Net Change VGTNegative Net Change QTECNegative Net Change
biotechs etfs tech-stocks
Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.
RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change PRTANegative Net Change
biotechs
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.
RHHBYNegative Net Change IRWDNegative Net Change PBYINegative Net Change LRMRNegative Net Change
biotechs
Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.
VRTXNegative Net Change HZNPPositive Net Change RGENNegative Net Change FOLDPositive Net Change
biotechs
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
JNJPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs earnings
Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.
NVSPositive Net Change BMYNegative Net Change INCYPositive Net Change XLRNPositive Net Change
biotechs earnings pharmaceuticals
Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.
RHHBYNegative Net Change BMYNegative Net Change EXELPositive Net Change RGENNegative Net Change
biotechs earnings pharmaceuticals
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
RDYPositive Net Change TEVANegative Net Change VRTXNegative Net Change AMRNNegative Net Change
biotechs earnings
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
HALOPositive Net Change RUBYNegative Net Change SPRBNegative Net Change
biotechs
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.
MRKPositive Net Change RGENNegative Net Change CLLSNegative Net Change IOVAPositive Net Change
biotechs
Ocugen's (OCGN) Q2 Earnings Miss Estimates, Stock Down
by Zacks Equity Research
Ocugen (OCGN) miss earnings estimates in the second quarter of 2021. Stock down.
OCGNNegative Net Change
biotechs
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up
by Zacks Equity Research
Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.
VRTXNegative Net Change HZNPPositive Net Change RGENNegative Net Change ARWRNegative Net Change
biotechs earnings
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the second quarter.
BMYNegative Net Change JNJPositive Net Change GILDPositive Net Change FATENegative Net Change
biotechs earnings
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.
BMYNegative Net Change VRTXNegative Net Change RGENNegative Net Change CLVSPositive Net Change
biotechs
Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.
AZNNegative Net Change MRKPositive Net Change VRTXNegative Net Change MRNAPositive Net Change
biotechs earnings
Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechs earnings pharmaceuticals
Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.
RGENNegative Net Change VNDAPositive Net Change ALLONegative Net Change
biotechs earnings
Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.
RHHBYNegative Net Change RGENNegative Net Change SRPTNegative Net Change VNDAPositive Net Change
biotechs earnings
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
SNYPositive Net Change RGENNegative Net Change TECHNegative Net Change GBTPositive Net Change
biotechs earnings
Amgen (AMGN) Q2 Earnings Top, COVID-Led Sales Woes to Linger
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It expects the pandemic to continue to hurt sales growth in the second half of 2021.
RHHBYNegative Net Change BMYNegative Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.
VRTXNegative Net Change RGENNegative Net Change VNDAPositive Net Change DCPHPositive Net Change
biotechs
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
SNYPositive Net Change AAPLNegative Net Change TGTPositive Net Change WMTPositive Net Change MRNAPositive Net Change IBBNegative Net Change TBIONegative Net Change FBNegative Net Change GOOGLNegative Net Change XBINegative Net Change BBHPositive Net Change FBTNegative Net Change BTECPositive Net Change
biotechs etfs
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.
VRTXNegative Net Change RGENNegative Net Change VNDAPositive Net Change RARENegative Net Change
biotechs earnings
Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the second quarter as Jakafi sales register growth.
NVSPositive Net Change LLYNegative Net Change INCYPositive Net Change MORPositive Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.
IRWDNegative Net Change MRNAPositive Net Change PRTANegative Net Change OCGNNegative Net Change
biotechs